Document is current
Any future updates will be listed below
-
Authors
Yamamura, Shogo https://orcid.org/0009-0005-4228-3963
Kanai, Masashi
Takeuchi, Yasuhide
Okita, Natsuko
Kondo, Tomohiro
Yoshioka, Masahiro
Matsubara, Junichi
Matsumoto, Shigemi
Muto, Manabu
- License Information
-
More Information
Article History
Received: 20 September 2023
Accepted: 26 November 2023
First Online: 2 January 2024
Declarations
:
: Masashi Kanai own stocks in Therabiopharma and received honoraria from Chugai Pharmaceutical Co., Ltd. Taro Funakoshi belongs to an endowed chair sponsored partly by Yakult Honsha Co., Ltd. and Chugai Pharmaceutical Co., Ltd. Manabu Muto received research funding and honoraria from Chugai Pharmaceutical Co., Ltd. All remaining authors have no conflict of interest to declare.
: This report was supported by research on “The prospective trial of patient-proposed healthcare services with multiple targeted agent based on the result of gene profiling by multigene panel test (NCCH1901/jRCTs031190104)” of the Clinical Research Review Committee, National Cancer Center Hospital, under Grant number CRB3180008.
: We obtained consent of the patient for participating in the NCCH1901 study and publication related to this study. A copy of the consent form with the patient's signature can be submitted.
